This activity is provided by National Jewish Health.

This educational activity is supported by an educational grant from Eli Lilly.

Credit Available

• Physicians – 1.0 AMA PRA Category 1 Credit™
• Pharmacists - 1.0 contact hour (0.10 CEUs)
• Registered Nurses - 1.0 nursing contact hour

All other health care professionals completing this course will be issued a statement of participation.

Target Audience

The primary intended audience for this education includes practicing US HCPs who are involved in the care and treatment of patients with COVID-19 in an outpatient setting, including physicians, NPs, PAs, registered nurses, and pharmacists.

Learning Objectives

Upon completion of this activity, participants should be better able to:

• Recognize SARS-CoV-2-infected patients with mild to moderate COVID-19 who could benefit from NaBs treatments
• Counsel and orient SARS-CoV-2-infected patients displaying mild to moderate symptoms to appropriate treatment or care based on their risk for hospitalization.

Live Activity

Friday, May 21, 2021 at 5:00 pm EST

Enduring Material

May 21, 2021 – May 21, 2022

Accreditation Statement

National Jewish Health is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

National Jewish Health is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Credit Designation

• National Jewish Health designates this activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
• Provider approved by the California Board of Registered Nursing, Provider Number 12724 for 1.0 nursing contact hours.
• National Jewish Health designates this live activity for 1.0 contact hour (0.10 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number: 0831-0000-21-017-L01-P. Activity Type: Knowledge-based.
• To earn credit, attendees must participate in the live activity, pass the post-test with a minimum score of 70%, and complete the activity evaluation.

Disclosure of Financial Relationships

In accordance with the Accreditation Council for Continuing Medical Education (ACCME), National Jewish Health requires that all program faculty, content developers, reviewers, and others in a position to control the content of this activity disclose to learners the presence or absence of any relevant financial relationships with an ACCME-defined ineligible company. The ACCME defines an “ineligible company” as one whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Our goal is to ensure that there is no compromise in the ethical relationship that exists between those in a position to control the content of the activity and those participating in the activity and their respective professional duties. All accredited education activities offered by National Jewish Health are reviewed to ensure a balanced and evidence-based presentation.

All relevant financial relationships among individuals in a position to control the content of this activity have been identified and mitigated according to the Standards of Integrity and Independence in Accredited Education.

Faculty Disclosures

Jared J. Eddy, MD, MPhil, MSc declares he has no relevant financial relationships to disclose.
Rebecca C. Keith, MD discloses she is a speaker for Boehringer Ingelheim and Genentech.

Planners and Reviewers

Meghan Brenner, MA declares she has no relevant financial relationships to disclose.
Carole Drexel, PhD declares she has no relevant financial relationships to disclose.
James Finigan, MD discloses he is a consultant for EMD Serono and AstraZeneca.

Andrea Harshman, MHA, CHCP, CMP-HC declares she has no relevant financial relationships to disclose.
Lyndon B. Reynoso, MSHA, RPh declares he has no relevant financial relationships to disclose.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.

No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports.

Please refer to the official prescribing information for each product for discussion of approved indicators, contraindications and warnings.

Disclaimer

National Jewish Health ("NJH") and its officers, Board of Directors, faculty, employees, representatives, and other agents (collectively, "NJH Parties") shall not be responsible in any capacity for, and do not warrant any content whatsoever, in any NJH publication or other product (in any medium), or the use or reliance on any such content, and expressly disclaim any and all liability for such content. All such responsibility for content and use of product solely rests with the authors or the advertisers, as the case may be.

By way of example, without limiting the foregoing, this disclaimer of liability applies to the accuracy, completeness, effectiveness, quality, appearance, ideas, or products, as the case may be, of or resulting from, any statements, references, articles, positions, claimed diagnosis, claimed possible treatments, services, or advertising, express or implied, contained in any NJH live meeting, publication, online course or other product.

Furthermore, the content should not be considered medical advice and is not intended to replace consultation with a qualified medical professional. Under no circumstances, including negligence, shall any of the NJH Parties be liable for any DIRECT, INDIRECT, INCIDENTAL, SPECIAL or CONSEQUENTIAL DAMAGES, or LOST PROFITS that result from any of the foregoing, regardless of legal theory and whether or not claimant was advised of the possibility of such damages.